Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Immunol. 2013 Dec 9;192(1):59–72. doi: 10.4049/jimmunol.1301513

Figure 8. Effect of AZD1480 on Th1- and Th17-induced Adoptive Transfer EAE.

Figure 8

(A). C57BL/6 mice were immunized with MOG35-55 peptide (200 μg) for 10 days, splenocytes and lymph node cells were isolated, then MOG-specific T-cells were cultured with MOG35-55 peptide (10 μg/ml) under Th1 differentiation conditions for 3 days. Thirty × 106 cells were injected i.v.into C57BL/6 mice. Vehicle Control (n=10) or AZD1480 (25 mg/kg) (n=11) was administrated daily by i.p. starting at day 7 for 10 days. Mean ± S.D. of classical EAE clinical scores. (B). Mice were perfused, spinal cord removed, and protein extracts from spinal cord of Vehicle Control or AZD1480 treated mice at day 17 were immunoblotted with the indicated antibodies. (C). Mice were perfused, spinal cord removed, and mRNA from Vehicle Control or AZD1480 treated mice at day 17 was analyzed by qRT-PCR. (D). C57BL/6 mice were immunized with MOG35-55 peptide (200 μg) for 10 days, splenocytes and lymph node cells were isolated, then MOG-specific T-cells were cultured with MOG35-55 peptide (10 μg/ml) under Th17 differentiation conditions for 3 days. Thirty × 106 cells were injected i.v. into C57BL/6 mice. Vehicle Control (n=11) or AZD1480 (25 mg/kg) (n=10) was administrated daily by i.p. starting at day 8 for 10 days. Mean ± S.D. of classical EAE clinical scores. (E). Mice were perfused, spinal cord removed, and protein extracts from spinal cord of Vehicle Control or AZD1480 treated mice at day 18 were immunoblotted with the indicated antibodies. (F). Mice were perfused, spinal cord removed, and mRNA from spinal cord of Vehicle Control or AZD1480 treated mice at day 18 was analyzed by qRT-PCR. *p<0.05 and **p<0.001.